Iron chelators ICL670 and 311 inhibit HIV-1 transcription

Virology

Volumn 367, Issue 2, 2007, Pages 324-333

  Debebe, Zufan ^a   Ammosova, Tatyana ^a   Jerebtsova, Marina ^c   Kurantsin Mills, Joseph ^a   Niu, Xiaomei ^a   Charles, Sharroya ^a   Richardson, Des R ^b   Ray, Patricio E ^c   Gordeuk, Victor R ^a   Nekhai, Sergei ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

2 Hydroxy 1 naphthylaldehyde isonicotinoyl hydrazone (311); 4 3,5 bis (hydroxyphenyl) 1,2,4 triazol 1 yl benzoic acid (ICL670); CDK2; CDK9; Desferrioxamine (DFO); HIV 1; Iron; Iron chelation; Transcription

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; DEFERASIROX; IRON CHELATING AGENT; ISONIAZID DERIVATIVE; RNA POLYMERASE II; SERINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; IRON CHELATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

BENZOIC ACIDS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; GENE EXPRESSION REGULATION, VIRAL; HIV-1; HUMANS; IRON; IRON CHELATING AGENTS; ISONIAZID; TRANSCRIPTION, GENETIC; TRIAZOLES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34848927142     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.06.011     Document Type: Article

References (38)

1. Agbottah E., de La Fuente C., Nekhai S., Barnett A., Gianella-Borradori A., Pumfery A., and Kashanchi F. Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 280 4 (2005) 3029-3042
2. Ammosova T., Jerebtsova M., Beullens M., Voloshin Y., Ray P.E., Kumar A., Bollen M., and Nekhai S. Nuclear protein phosphatase-1 regulates HIV-1 transcription. J. Biol. Chem. 278 34 (2003) 32189-32194
3. Ammosova T., Berro R., Kashanchi F., and Nekhai S. RNA interference directed to CDK2 inhibits HIV-1 transcription. Virology 341 2 (2005) 171-178
4. Ammosova T., Jerebtsova M., Beullens M., Lesage B., Jackson A., Kashanchi F., Southerland W., Gordeuk V.R., Bollen M., and Nekhai S. Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein. J. Biol. Chem. 280 43 (2005) 36364-36371
5. Ammosova T., Berro R., Jerebtsova M., Jackson A., Charles S., Klase Z., Southerland W., Gordeuk V.R., Kashanchi F., and Nekhai S. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3 (2006) 78
6. Berthet C., Aleem E., Coppola V., Tessarollo L., and Kaldis P. Cdk2 knockout mice are viable. Curr. Biol. 13 20 (2003) 1775-1785
7. Bieniasz P.D., Grdina T.A., Bogerd H.P., and Cullen B.R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17 23 (1998) 7056-7065
8. Brenner S., and Malech H.L. Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. Biochim. Biophys. Acta 1640 1 (2003) 1-24
9. Coulonval K., Bockstaele L., Paternot S., and Roger P.P. Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis. J. Biol. Chem. 278 52 (2003) 52052-52060
10. Deng L., Ammosova T., Pumfery A., Kashanchi F., and Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J. Biol. Chem. 277 37 (2002) 33922-33929
11. Frankel A.D., and Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 6 (1988) 1189-1193
12. Fu D., and Richardson D.R. Iron chelation and regulation of the cell-cycle: two mechanisms of post-transcriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood (2007)
13. Galanello R., Piga A., Alberti D., Rouan M.C., Bigler H., and Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J. Clin. Pharmacol. 43 6 (2003) 565-572
14. Gao J., and Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98 3 (2001) 842-850
15. Garber M.E., Wei P., and Jones K.A. HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Cold Spring Harbor Symp. Quant. Biol. 63 (1998) 371-380
16. Garber M.E., Wei P., KewalRamani V.N., Mayall T.P., Herrmann C.H., Rice A.P., Littman D.R., and Jones K.A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12 22 (1998) 3512-3527
17. Georgiou N.A., van der Bruggen T., Oudshoorn M., Nottet H.S., Marx J.J., and van Asbeck B.S. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J. Infect. Dis. 181 2 (2000) 484-490
18. Georgiou N.A., van der Bruggen T., Oudshoorn M., Hider R.C., Marx J.J., and van Asbeck B.S. Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. Eur. J. Clin. Invest. 32 Suppl. 1 (2002) 91-96
19. Gordeuk V.R., Delanghe J.R., Langlois M.R., and Boelaert J.R. Iron status and the outcome of HIV infection: an overview. J. Clin. Virol. 20 3 (2001) 111-115
20. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., and Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69 11 (1995) 6705-6711
21. Kashanchi F., Agbottah E.T., Pise-Masison C.A., Mahieux R., Duvall J., Kumar A., and Brady J.N. Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator. J. Virol. 74 2 (2000) 652-660
22. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66 4 (1992) 2232-2239
23. Liang W.S., Maddukuri A., Teslovich T.M., de la Fuente C., Agbottah E., Dadgar S., Kehn K., Hautaniemi S., Pumfery A., Stephan D.A., and Kashanchi F. Therapeutic targets for HIV-1 infection in the host proteome. Retrovirology 2 1 (2005) 20
24. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13 (1997) 261-291
25. Nekhai S., and Jeang K.-T. Transcriptional and posttranscriptional regulation of HIV-1 gene expression: role of cellular factor. Future Microbiology 4 (2006) 417-426
26. Nekhai S., Bottaro D.P., Woldehawariat G., Spellerberg A., and Petryshyn R. A cell-permeable peptide inhibits activation of PKR and enhances cell proliferation. Peptides 21 10 (2000) 1449-1456
27. Nekhai S., Shukla R.R., Fernandez A., Kumar A., and Lamb N.J. Cell cycle-dependent stimulation of the HIV-1 promoter by Tat-associated CAK activator. Virology 266 2 (2000) 246-256
28. Nekhai S., Zhou M., Fernandez A., Lane W.S., Lamb N.J., Brady J., and Kumar A. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem. J. 364 Pt 3 (2002) 649-657
29. Nekhai S., Bhat U.G., Ammosova T., Radhakrishnan S.K., Jerebtsova M., Niu X., Foster A., Layden T.J., and Gartel A.L. A novel anticancer agent ARC antagonizes HIV-1 and HCV. Oncogene 26 (2007) 3899-3903
30. Nekhai S., Jerebtsova M., Jackson A., and Southerland W. Regulation of HIV-1 transcription by protein phosphatase 1. Curr. HIV Res. 5 1 (2007) 3-9
31. Porter J.B. Deferasirox: an effective once-daily orally active iron chelator. Drugs Today (Barc) 42 10 (2006) 623-637
32. Richardson D.R., and Bernhardt P.V. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J. Biol. Inorg. Chem. 4 3 (1999) 266-273
33. Schagger H., Bentlage H., Ruitenbeek W., Pfeiffer K., Rotter S., Rother C., Bottcher-Purkl A., and Lodemann E. Electrophoretic separation of multiprotein complexes from blood platelets and cell lines: technique for the analysis of diseases with defects in oxidative phosphorylation. Electrophoresis 17 4 (1996) 709-714
34. Traore H.N., and Meyer D. The effect of iron overload on in vitro HIV-1 infection. J. Clin. Virol. 31 Suppl. 1 (2004) S92-S98
35. Wei P., Garber M.E., Fang S.M., Fischer W.H., and Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92 4 (1998) 451-462
36. Yang X., Gold M.O., Tang D.N., Lewis D.E., Aguilar-Cordova E., Rice A.P., and Herrmann C.H. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. U. S. A. 94 23 (1997) 12331-12336
37. Yoon G., Kim H.J., Yoon Y.S., Cho H., Lim I.K., and Lee J.H. Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor beta1 (TGF-beta1)-mediated p27Kip1 expression. Biochem. J. 366 Pt 2 (2002) 613-621
38. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M.B., and Price D.H. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11 20 (1997) 2622-2632